The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

The benefit was seen in both HER2-low and HER2-ultra-low patients, prompting investigators to suggest that Enhertu could become a new standard of care for patients with HER2-low- and HER2-ultra ...